Title | Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Prutsch N, Gurnhofer E, Suske T, Liang HChang, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Sternberg C, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, A Look T, Turner SD, Kenner L, Merkel O |
Journal | Leukemia |
Volume | 33 |
Issue | 3 |
Pagination | 696-709 |
Date Published | 2019 03 |
ISSN | 1476-5551 |
Keywords | Anaplastic Lymphoma Kinase, Animals, Apoptosis, Cell Line, Tumor, Cell Survival, Gene Expression Regulation, Neoplastic, Humans, Lymphoma, Large-Cell, Anaplastic, Mice, Myeloid Cell Leukemia Sequence 1 Protein, Phosphorylation, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Signal Transduction, STAT1 Transcription Factor, STAT3 Transcription Factor, Translocation, Genetic, TYK2 Kinase |
Abstract | TYK2 is a member of the JAK family of tyrosine kinases that is involved in chromosomal translocation-induced fusion proteins found in anaplastic large cell lymphomas (ALCL) that lack rearrangements activating the anaplastic lymphoma kinase (ALK). Here we demonstrate that TYK2 is highly expressed in all cases of human ALCL, and that in a mouse model of NPM-ALK-induced lymphoma, genetic disruption of Tyk2 delays the onset of tumors and prolongs survival of the mice. Lymphomas in this model lacking Tyk2 have reduced STAT1 and STAT3 phosphorylation and reduced expression of Mcl1, a pro-survival member of the BCL2 family. These findings in mice are mirrored in human ALCL cell lines, in which TYK2 is activated by autocrine production of IL-10 and IL-22 and by interaction with specific receptors expressed by the cells. Activated TYK2 leads to STAT1 and STAT3 phosphorylation, activated expression of MCL1 and aberrant ALCL cell survival. Moreover, TYK2 inhibitors are able to induce apoptosis in ALCL cells, regardless of the presence or absence of an ALK-fusion. Thus, TYK2 is a dependency that is required for ALCL cell survival through activation of MCL1 expression. TYK2 represents an attractive drug target due to its essential enzymatic domain, and TYK2-specific inhibitors show promise as novel targeted inhibitors for ALCL. |
DOI | 10.1038/s41375-018-0239-1 |
Alternate Journal | Leukemia |
PubMed ID | 30131584 |
PubMed Central ID | PMC8076043 |
Grant List | P 27132 / FWF_ / Austrian Science Fund FWF / Austria 14856 / / Oesterreichische Nationalbank (Austrian National Bank) / International |
Related Faculty:
Giorgio Inghirami, M.D.